Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | CPB1 | P15086 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964511 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL8624147 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL21372487 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL8625496 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL8621283 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL8989234 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL5964669 | 0.99 | CPB2 (0.53) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL5964745 | 0.96 | CPB2 (0.51) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL8625507 | 0.94 | SLC6A5 (0.53) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL6937530 | 0.92 | CPB2 (0.44) | CPB2ITGB3ITGA2BCPB1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47320-E1 | Modulation of CD40 expression | IONIS PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2125031-B1 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | MARINA BIOTECH INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2222851-B1 | MODULATION OF CD40 EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20150299803-A1 | Methods of Using Biomarkers for the Treatment of Cancer by Modulation of BCL2 Expression | PRONAI THERAPEUTICS, INC. | 2015-10-22 | — | — | US | disclosed |
| US-20150291960-A1 | MODULATION OF CD40 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150272980-A1 | Dosing and Administration of Oligonucleotide Cancer Therapies | PRONAI THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| EP-2914722-A1 | DOSING AND ADMINISTRATION OF OLIGONUCLEOTIDE CANCER THERAPIES | Pronai Therapeutics, Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150118291-A1 | Amphoteric Liposome Formulation | NOVOSOM VERWALTUNGS GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-8916531-B2 | Modulation of CD40 expression | ISIS PHARMACEUTICALS, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140178462-A1 | AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS | MARINA BIOTECH, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20060159737-A1 | Pharmaceutical compositions for local administration | NOVOSOM AG (DE) | 2006-07-20 | — | — | US | disclosed |
| US-20060147511-A1 | Liposomal glucocorticoids | PANZNER STEFFEN | 2006-07-06 | — | — | US | disclosed |
| WO-2006053646-A2 | IMPROVEMENTS IN OR RELATING TO PHARMACEUTICAL COMPOSITIONS FOR LOCAL ADMINISTRATION | NOVOSOM AG (DE) | 2006-05-26 | — | — | WO | disclosed |
| EP-1658839-A1 | Oligonucleotide/carrier combinations targeting CD40 | Novosom AG (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2006048329-A1 | IMPROVEMENTS IN OR RELATING TO PHARMACEUTICAL COMPOSITIONS COMPRISING AN OLIGONUCLEOTIDE AS AN ACTIVE AGENT | NOVOSOM AG (DE) | 2006-05-11 | — | — | WO | disclosed |
| WO-2005094783-A2 | SERUM-STABLE AMPHOTERIC LIPOSOMES | NOVOSOM AG (DE) | 2005-10-13 | — | — | WO | disclosed |
| EP-1581185-A2 | LIPOSOMAL GLUCOCORTICOIDS | Novosom AG (DE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004047792-A2 | LIPOSOMAL GLUCOCORTICOIDS | NOVOSOM AG (DE) | 2004-06-10 | — | — | WO | disclosed |
| US-5503776-A | PROTECTIVE COATINGS, EMULSIFIERS, BACTERICIDES, ULTRAVIOLET ABSORBERS, CHELATING | NATIONAL FOOD RESEARCH INSTITUTE MINISTRY OF AGRICULTURE, FORESTRY AND FISHERIES (JP) | 1996-04-02 | — | — | US | disclosed |
| EP-0500332-A2 | Novel acylamino acid compounds and a method for their production | NATIONAL FOOD RESEARCH INSTITUTE MINISTRY OF AGRICULTURE, FORESTRY AND FISHERIES (JP) | 1992-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118291-A1 | Amphoteric Liposome Formulation | ANXA5, ANXA11, CLPTM1L | CPB2 3842/4885ITGB3 3689/4885ITGA2B 2362/4885 |
| US-20060159737-A1 | Pharmaceutical compositions for local administration | LIPA, GOT1, CHMP4B | CPB2 3688/4885ITGB3 4200/4885ITGA2B 3544/4885 |
| US-20150272980-A1 | Dosing and Administration of Oligonucleotide Cancer Therapies | BCL2, BCL2L11, BCL2A1 | CPB2 2788/4885ITGB3 3304/4885ITGA2B 2543/4885 |
| US-20140178462-A1 | AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS | LIPA, CETP, SGMS1 | CPB2 3858/4885ITGB3 3662/4885ITGA2B 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.